Merck Pushes Discount Zocor; Health Plans Are Wary, But Pfizer Is Concerned
Executive Summary
The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward